Abstract
#Piroxiam is an #oxicam derivative medication belonging to non
steroidal #anti-inflammatorydrugs (NSAIDs) group, used to treat moderate
to severe inflammatory diseases such as rheumatoid arthritis,
#osteoarthritis, ankylosing #spondylitis (Bechterew’s disease),
tendinitis, bursitis,
and for pain that is not related to #musculoskeletalsystem e.g. primary
#dysmenorrhea and postoperative pain. It reduces pain, joint swelling,
morning stiffness, and improves the functionality of the joints during
chronic #polyarthritis. Piroxicam has been compared to other
antiinflammatory
agents (e.g. diclofenac, #indomethacin, and #naproxen) in numerous
controlled studies and proved to be equal and sometimes even
more efficacious. Piroxicam is unique among NSAIDs in that it is used
once daily, and its efficacy is equal to most important clinically
employed
NSADs (ibuprofen, naproxen and diclofenac) especially in amelioration of
postoperative pain, but it is more prone to causing gastrointestinal
disturbances and serious skin reactions (Steven-Johnsons syndrome, toxic
epidermal necrolysis). It should not be given to patients who have
experienced peptic ulcer, asthma, urticaria or allergic-type reactions
after taking aspirin or other NSAIDs, as well as patients on
anticoagulant
therapy, renal, #hepatic, #diabetic and cardiac patients.
#Piroxicam- Induced #Hepatotoxicity by Omar Rashid Sadeq in BJSTR
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.